TY - JOUR
T1 - Quality of life as a treatment outcome in patients with cystic fibrosis
AU - Munzenberger, Paul J.
AU - Van Wagnen, Catherine A.
AU - Abdulhamid, Ibrahim
AU - Walker, Paul C.
PY - 1999
Y1 - 1999
N2 - We attempted to determine the responsiveness and validity of the Quality of Well-Being (QWB) scale in 20 consecutive children and adolescents with cystic fibrosis. The QWB score was determined for 6-day periods immediately before and after hospital admission, and at 6- and 12-month follow-up. With the instrument's scale of zero-1, responsiveness was indicated by significant changes in QWB score (0.09), physical (0.019), social (0.021), and symptom- problem complexes (0.04) domains, and all pulmonary function tests from before to after treatment of an acute exacerbation. Only the symptom-problem complex domain significantly changed from after treatment to 6- and 12-month follow-up. Validity was shown by significant correlations between before and after QWB scores and forced vital capacity (r=0.476), residual volume total lung capacity ratio (r=0.452), forced expiratory volume in 1 second (r=0.358), and forced expiratory flow between 25% and 75% of vital capacity (r=0.35).
AB - We attempted to determine the responsiveness and validity of the Quality of Well-Being (QWB) scale in 20 consecutive children and adolescents with cystic fibrosis. The QWB score was determined for 6-day periods immediately before and after hospital admission, and at 6- and 12-month follow-up. With the instrument's scale of zero-1, responsiveness was indicated by significant changes in QWB score (0.09), physical (0.019), social (0.021), and symptom- problem complexes (0.04) domains, and all pulmonary function tests from before to after treatment of an acute exacerbation. Only the symptom-problem complex domain significantly changed from after treatment to 6- and 12-month follow-up. Validity was shown by significant correlations between before and after QWB scores and forced vital capacity (r=0.476), residual volume total lung capacity ratio (r=0.452), forced expiratory volume in 1 second (r=0.358), and forced expiratory flow between 25% and 75% of vital capacity (r=0.35).
UR - http://www.scopus.com/inward/record.url?scp=0032923634&partnerID=8YFLogxK
U2 - 10.1592/phco.19.6.393.31047
DO - 10.1592/phco.19.6.393.31047
M3 - Article
C2 - 10212009
AN - SCOPUS:0032923634
SN - 0277-0008
VL - 19
SP - 393
EP - 398
JO - Pharmacotherapy
JF - Pharmacotherapy
IS - 4 I
ER -